Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for chronic urticaria
ACTRN12611001095954Phase 4Recruiting
- Sponsor
- Senior doctor Claus Zachariae
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of adalimumab in chronic urticaria (CU), sponsored by Senior doctor Claus Zachariae. Primary endpoint: Urticaria Activity Score at Week 28. Started Aug 2011; status: recruiting.
02
Drugs
03
Conditions
chronic urticaria (CU)
Beyond the preview
Go deeper on ACTRN12611001095954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001095954.